Introduction
Fibromyalgia (FM) is a common pain syndrome accompanied by other symptoms such as tender spots, decreased pain threshold, fatigue, headache, sleep disturbances, and depression. It is a chronic condition characterized by a pattern of vague symptoms that are difficult to diagnose and treat. FM is diagnosed according to the classification criteria established by the American College of Rheumatology (ACR) (Wolfe et al., 1990 ) and routine laboratory investigations usually yield normal results (Yunus et al., 1981) . The prevalence of FM in industrialized countries ranges from 0,4% to 4% (it affects at least 5 million individuals in the United States and 800.000 in Spain) in the population being 11 time more frequent in women than in men (Lawrence et el., 2008) . Its high prevalence makes fibromyalgia a major problem in developed countries in the recent years. FM causes work absenteeism and has been associated with high medical services utilization cost and considerable disability. Furthermore, the use of medications and medical necessities increased markedly across many measures once diagnosis was made. It has been estimated that annual health service cost of FM patients was twice that of patients with chronic widespread pain and pain-free controls. The fact that its diagnostic criteria are only clinical, and that its etiopathogenesis has not yet been clarified makes very difficult the study and therapeutical approach of the disease. Although the etiology of FM remains unclear, evidence suggests that biologic, genetic, and environmental factors are involved.It is considered that the changes in the neuronal activity in the central nervous system, abnormal metabolism of biogenic amines, immunological disorders and oxidative stress may among others factors contribute to the development of the disease. For all these reasons is urgent to do more research in the diagnosis, pathophysiology and therapy of FM. Fibromyalgia syndrome has been related to disturbances of hypothalamic-pituitary axis together with neurotransmission imbalance, involving excitatory amino acids, (Cohen & Gold, 2001 ).
Furthermore, ROS have an established role in inflammation. Increased levels of Inflammatory mediators such as tumor necrosis factor alpha (TNF-) and interleukins, have been associated with mitochondrial dysfunction and increased ROS generation (Naik & Dixit, 2011) , and it has been hypothesized that abnormal production of cytokines may play a role in the pathogenesis of FM (Wallace et al, 2001 ). IL-1, IL-6 and IL-8 are dysregulated in the syndrome and therapies directed against these cytokines may be of potential importance in the management of fibromyalgia (Wallace, 2006) . However, different studies with conflicting results (Uçeyler et al, 2006; Bazzichi et al, 2007) make necessary more studies to better understand the role of cytokines in FM.
Mitochondrial dysfunction in FM
Because the main symptoms in FM (pain, stiffness and fatigue) are located in the muscles, muscle biopsies, mostly from the trapezious, have been studied. In most cases, mitochondrial morphologic alterations have been found in muscle biopsies from FM patients. Histochemical analysis demonstrated type II fiber atrophy and the "moth-eaten" appearance of type I fibers. Electron microscopic findings were most impressive, and included, subsarcolemmal mitochondrial accumulation (Kalyan-Raman et al., 1984) , myofibrillarlysis with deposition of glycogen and abnormal mitochondria (Yunus et al., 1986) , low number of mitochondria (Sprott et al., 2004) , electrons-dense inclusions and lack of inner membrane (Hénriksson et al., 1982) , ragged red fibres (Bengtsson et al., 1988) , and single fiber defects of cytochrome-c-oxidase, the complex IV of oxidative phosphorilation (Drewes et al., 1993 , Pöngratz & Späth, 1998 . The presence of moth-eaten and ragged-red fibres indicates uneven distribution and proliferation of mitochondria. Accumulation of mitochondria is seen in Gomori trichrome staining, and this gives the ragged appearance.
Mitochondrial proliferation may be a compensatory phenomenon in disorders or pathophysiological states affecting oxidative metabolism (Bengtsson, 2002) . It is interesting to mention that ragged red fibres, subsarcolemmal mitochondrial accumulation and alteration in ultrastructure, number and size of mitochondrial are typical defects and markers found in genuine mitochondrial diseases (MELAS, MERRF, Kearns-Sayre syndrome, Pearson syndrome, Leigh syndrome, etc) (Haas et al., 2008) . However, red ragged fibers appear to be also related to insufficient blood supply (Heffner & Barron, 1978) , and abnormal capillary microcirculation in tender points was found in FM patients (Lund et al, 1986) . Microcirculation in the muscle is controlled by the sympathetic nervous system and others local and humoral factors. Therefore, the contribution of the vasoconstrictor activity of the sympathetic nervous system that produces local hypoxia in muscle and fiber damage should be considered in the pathogenesis of red ragged fibers in FM. 31 P Magnetic Resonance Spectroscopy (MRS) analysis in muscle has provided objective evidence for metabolic abnormalities consistent with clinical symptoms of weakness and fatigue in patients with FM (Park et al., 1998) . The MRS examinations showed phosphocreatine (PCr) and ATP concentrations in muscles of FM patients to be 15% below normal values during rest and exercise. The reduced levels of PCr and ATP in the patients' muscles correlate with clinical observations regarding weakness and pain during exercise. In this study, pain was inversely correlated with ATP and PCr levels. Reduction in ATP levels also has been observed in the erythrocytes of FM patients, suggesting that this may be a more systemic phenomenon than was previously assumed (Russell et al, 1993) . Recently, it has also been noted a decrease of ATP levels in platelets from FM patients (Bazzichi et al., 2008) . Blood platelets represent an easily available and simple peripheral model to study bioenergetics alterations in FM. Platelets possess mitochondria, the entire pool of enzymes or proteins involved in oxidative energy production and, consequently, they are active in ATP turnover (Niu et al, 1996) . Moreover, platelets present on their plasma membrane either pain/inflammation or neurochemical sites, such as adenosine/monoamine receptors and transporters (Marazziti et al, 1999; Martini et al, 2004) , enabling the study of either neurochemistry or ATP energy metabolism in FM. Some recent have shown a significant increase of the platelet peripheral benzodiazepine receptor (PBR) (now named traslocator protein, TSPO, (Papadopoulos et al, 2006) together with high plasma levels of the pro-inflammatory chemokine interleukine 8 (IL-8), low serum cortisol (Bazzichi et al, 2006a) as well as a reduced density and functionality of the platelet serotonin transporter (SERT) (Bazzichi et al , 2006b ) in FM patients.
Mitochondrial dysfunction, oxidative stress in FM
In general, oxidative stress could be defined as an imbalance between the presence of high levels of ROS and reactive nitrogen species (RNS), and the antioxidative defense mechanisms. These toxic molecules are formed via oxidation-reduction reactions and are highly reactive since they have an odd number of electrons. ROS generated under physiological conditions are essential for life, as they are involved in bactericidal activity of phagocytes, and in signal transduction pathways, regulating cell growth and reductionoxidation (redox) status (Davies, 1995) . ROS includes free radicals, such as hydroxyl and superoxide radicals, and non-radicals, including hydrogen peroxide and singlet oxygen.
Oxidative stress and generation of free radicals, as primary or secondary event, have been related in a great number of diseases. It has been suggested that oxidative stress is linked to www.intechopen.com
The Role of Oxidative Stress and Mitochondrial Dysfunction in the Pathogenesis of Fibromyalgia 83 both the initiation and the progression of Parkinson´s disease (Zhou et al., 2008) , and strong evidence exists for early oxidative stress in Huntington´s disease (Stack et al., 2008) .
Moreover, numerous studies demonstrate that different biomarkers of oxidative-stressmediated events are elevated in the Alzheimer disease (Praticò, 2008) and renal disease (even in early chronic kidney disease) (Cachofeiro et al., 2008) . Moreover, oxidative stress is believed to aggravate the symptoms of many diseases, including hemolytic anemias (Fibach & Rachmilewitz, 2008) , amyotrophic lateral sclerosis (Orrell et al., 2008) , and metabolic syndrome (Whaley-Connell et al., 2011) . It is known that ROS overproduction induces lipid peroxidation (LP) leading to oxidative destruction of polyunsaturated fatty acids, the main structural component of cellular membranes, and the production of toxic and reactive aldehyde metabolites such as malondialdehyde (MDA) and 4-hydroxynonenal (HNE) (Draper et al., 2000; Esterbauer et al., 1991) . These highly cytotoxic metabolites, produced in relatively large amounts, can diffuse from their site of origin to attack distant targets and form covalent bonds with various molecules. Therefore, recognition of LP is of interest, as the deleterious effects of this process might be prevented by administration of scavenging systems or antioxidants. In recent years, several studies have shown increased level of oxidative stress markers in FM suggesting that this process may have a role in the pathophysiology of this disease (Table 2) . High levels of LP and protein carbonyls are two of the most documented oxidative damage markers to be associated with FM. Thus, high levels of MDA, a final product of LP, and increased level of protein carbonyls, as result of protein oxidation have been reported in plasma from FM patients. Furthermore, it has been observed that total antioxidant capacity and superoxide dismutase (SOD), catalase and glutathione levels are reduced in FM patients. Furthermore, increased LP has been described in patients suffering from depression and fatigue, two typical symptoms found in FM patients (Bilici et al., 2001; Vecchiet et al., 2003) . Studies on depression have signaled a possible link between depression and LP (Evans, 2003) , and the peroxidation-reducing effect of different selective serotonin reuptake inhibitors in major depression has been demonstrated (Bilici et al., 2001) . It has been suggested that alterations in phospholipids which are structural components of cell membrane in the brain, may induce changes in membrane microviscosity and, consequently, in various neurotransmitter systems, which are thought be related to the pathology of depression, e.g., serotonin (5-HT), and noradrenaline (Maes et al., 1996; Tsutsumi et al., 1988) . LP of cell membranes can modify receptor accessibility, dynamics, ligand binding and action, and therefore altering neurotransmitter functions (Lenaz, 1987) . Oxidative stress may also affect the expression of membrane functional proteins and receptors, by interfering with intracellular signalling and receptors turnover, including serotonergic receptors (Maes et al., 2007) . The role of oxidative stress in peripheral neuropathic pain, one of the most prominent symptoms in FM, was recently also tested by assessing the effects of antioxidants (acetyl-Lcarnitine, alpha-lipoic acid, and vitamin C) on pain behaviour in a rat model of neuropathic pain induced by the antineoplastic agent oxaliplatin (Joseph et al., 2008) . Each agent, administered locally at the site of mechanical nociceptive testing in the skin, markedly inhibited the oxaliplatin-induced hyperalgesia. Finally, ROS also appear to contribute to hyperalgesia induced by PKCε (Joseph et al., 2010) , potentially linking this mitochondrial pathway to the hyperalgesic priming model of chronic peripheral pain. Furthermore, ROS are known to be implicated in the etiology of pain by inducing peripheral and central hyperalgesia (Wang et al., 2004 ). Superoxide plays a major role in the development of pain through direct peripheral sensitization, the release of various cytokines (for example, TNF-, IL-1 , and IL-6), the formation of peroxynitrite (ONOO-), and PARP activation (Wang et al., 2004) . Although, the mechanisms by which increased oxidative stress can affect specifically muscle sensitivity remain to be established, it may be that oxidative damage in muscles results in lowering the threshold of nociceptors locally, thus producing and altered nociception (Fulle et al., 2000) . In recent works, we have examined mitochondrial bioenergetics and antioxidant defenses in Blood mononuclears cells (BMCs) from FM patients. As CoQ deficiency had been suggested to be useful as a mitochondrial dysfunction marker, we addressed mitochondrial dysfunction in BMCs from FM patients and examined whether mitochondrial disturbance could be involved in the pathophysiology of oxidative stress in FM. We analyzed CoQ levels in BMCs and plasma from FM patients. We observed an altered distribution of CoQ levels between plasma and cells (high levels in plasma and low levels in cells) . We found that CoQ-deficient BMCs in FM patients showed high level of mitochondrial ROS production and increased levels of LP. To confirm oxidative stress in FM, BMCs of one representative patient were treated with three antioxidants (CoQ, vitamin E, and N-acetilcysteine) , and mitochondrial ROS production was examined. Both CoQ and vitamin E, two well known lipophilic antioxidants, induced a significantly reduction of ROS www.intechopen.com
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The Figure 2 ). These results suggest that ROS were produced in the lipophilic environment of mitochondrial membranes, and that CoQ deficiency may be involved in the oxidative stress observed in FM. In addition, biochemical analysis of citrate synthase indicated a depletion of mitochondrial mass, suggesting selective mitochondrial degradation in BMCs from FM patients. These results were confirmed by electron microscopy that clearly showed autophagosomes where mitochondria are being degraded (Figure 1 ). Mitophagy can be beneficial for the cells by eliminating dysfunctional mitochondria, but excessive mitophagy can promote cell injury and may contribute to the pathophysiology of FM (Cordero et al., 2010a) . In general, there is poor correlation between plasma and tissues levels of CoQ, and even patients with genetically proven CoQ deficiency may have plasma CoQ levels at a normal range. However, there is a positive correlation between the content of CoQ in skeletal muscle, dermal fibroblasts and BMCs (Land et al., 2007; Duncan et al., 2005) . Furthermore, mitochondrial dysfunction and oxidative stress has also been observed in skin biopsies from FM patients. The biopsies showed CoQ deficiency, increased level of LP, and a decrease in complex II + III and complex IV (Cordero et al., 2010b) . Interestingly, it is known that CoQ deficiency induces decreased activities of complex II + III, complex III and complex IV (Quinzii et al., 2008) . Furthermore, fibroblasts from skin of some patients with CoQ deficiency syndrome show a higher production of ROS in mitochondria (Quinzii et al., 2008) . Therefore, skin fibroblasts and BMCs can be helpful for biochemical diagnosis of mitochondrial defects in FM patients. As is shown in Table 2 , most of the studies about oxidative stress markers (MDA levels) in FM have used plasma or serum as experimental sample. However, it has to be taken into account that plasma or serum MDA levels depend on the balance between MDA formation and its detoxification and can be affected for many factors, such as the dilutional effect of plasma, and the renal and/or tissue clearance. Therefore, it would be desirable to measure oxidative stress markers in blood cells rather than in plasma o serum. On this point, it has recently been reported increased levels of hydrogen peroxide in neutrophils from FM patients (Kaufmann et al., 2008) . Interesting, there are some discrepancies about the correlation between symptoms and LP and oxidative stress in FM. Significant correlation has been observed between antioxidants levels in plasma and serum, visual analogue scale (VAS) of pain, and morning stiffness (Altindag & Celik, 2007; Sendur et al., 2009 ). However, Bagis et al. found no correlation between VAS of pain and LP or SOD in serum (Bagis et al., 2005) . On the other hand, Ozgocmen et al. found a significant correlation between depression and LP in serum but not between the biochemical parameters and clinical measures of pain and fatigue (Ozgocmen et al., 2006) . This controversy could be ascribed to a methodological problem because LP levels may show higher levels and reflect better the degree of oxidative stress if LP measurement is performed in cells rather than in plasma or serum. In fact, we have selected 65 FM patients and evaluated the association between LP and clinical symptoms ( Alternatively, as mentioned above, it has been observed low levels of SOD in plasma of FM patients (Bagis et al., 2005 , Ozgocmen et al., 2006 . SOD is an enzyme presents in all cells that catalyzes the conversion of superoxide free radicals to oxygen and hydrogen peroxide. It is the most powerful antioxidant produced by the body and has been used as a marker of antioxidant defense (Marklund SL (1990) . Therefore, SOD deficiency in FM may account for a low protection of cells against ROS damage and support the hypothesis of FM as an oxidative disorder. Besides mitochondrial dysfunction many others objective and measurable biomarkers has been proposed that may facilitate diagnosis and monitor the activity of FM (Dadabhoy et al, 2008) .
Control Patient
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Therapeutic implication of mitochondrial dysfunction in fibromyalgia
An important problem in FM is the moderate effectiveness of pharmacological therapies. In general, about half of all treated patients seem to experience a 30% reduction of symptoms, suggesting that many patients with fibromyalgia will require additional therapies (Staud, 2010) . But, in most cases, high incidence of secondary effects is induced by pharmacological therapy, and many drugs may induce mitochondrial damage (Neustadt & Pieczenik, 2008) . Mitochondria can be damaged both directly and indirectly by medications. Medications can directly inhibit mtDNA transcription of MRC complexes, damage through other mechanisms MRC components, and inhibit enzymes required for any of the steps of glycolysis and -oxidation. Indirectly, medications may damage mitochondrial via the production of free radicals, by decreasing endogenous antioxidants such as glutathione and by depleting the body of nutrients required for the creation or proper function of mitochondrial enzymes or MRC complexes. Damage to mitochondria may explain the side effects of many medications. Therefore, treatment with these drugs in patients with mitochondrial dysfunction could be counterproductive. In this respect, amitriptyline is a tricyclic antidepressant frequently recommended in FM treatment. There are evidences to support the short-term efficacy of amitriptilyne 25mg/day in FM (Nishishinya et al, 2008) . However, there is no evidence to support the efficacy of amitriptyline at higher doses or for periods longer than 8 weeks. Furthermore, amitriptyline causes a dose-related cytotoxic effect in neurons beginning at clinically relevant concentrations by a mechanism dependent on mitochondrial depolarization (Lirk et al, 2006) . Recently, our group has reported that amitriptyline at high doses induced CoQ deficiency and mitochondrial dysfunction in an in vitro cellular assay ). Moreover, CoQ and alpha-tocopherol supplementation prevented the cellular damage induced by amitriptyline. This data suggests that high dose or long-period of amitriptyline treatment should be done with caution monitoring mitochondrial function and, in case of CoQ deficiency, supplementing with CoQ could prevent its adverse effects. However, since oxidative stress may arise as a consequence of mitochondrial dysfunction or interfere with mitochondrial function, reducing oxidative stress emerges as a form of mitochondrial medicine that could be beneficial in FM patients. Thus, CoQ , frequently used in mitochondrial disease treatment to boost mitochondria function and prevent ROS damage (Tiano et al., 2011; Stack et al., 2008; Zhou et al., 2008; Quinzii & Hirano, 2010) , might be an alternative treatment in FM. Beneficial effects of CoQ administration in FM patients have been observed in a previous pilot study (Lister, 2002) . In this study, Lister et al reported beneficial effects of oral CoQ and Gingko Biloba supplementation in FM patients. They observed an important improvement in quality-of-life scores that justified the need for a larger scale clinical trial and further investigations into the possible mechanism of action of CoQ. In our studies, oral CoQ treatment significantly improved clinical symptoms and decrease oxidative stress in several cases of FM (Cordero et al., 2011a; Cordero e al., 2011b) . Nevertheless, more controlled clinical trials are needed to provide data on effectiveness of CoQ in FM. CoQ is a potential drug candidate in the treatment of FM for at least two main reasons. First, CoQ is a mitochondrial cofactor with the potential to improve mitochondrial function. Second, CoQ is a powerful free radical scavenger that can mitigate LP and DNA damage caused by oxidative stress (Lenaz G et al, 2007) . Thus, CoQ supplementation has been proven to be beneficial in patient with muscle pain associated with statin treatment (Caso et www.intechopen.com al., 2007) , and migraine prophylaxis (Sandor et al., 2005) . Furthermore, CoQ has shown antiinflammatory and anti-nociceptive activity (Jung et al., 2009) , regulating inflammatory gene expression as proinflammatory cytokine TNF-alpha (Schmelzer et al., 2008) which has been demonstrated to have a role in FM (Menzies et al., 2010) . Other antioxidants treatment has been assayed in FM. Melatonin, the pineal hormone with pleiotropic activity is a known powerful antioxidant and anti-inflammatory and increasing experimental and clinical evidence shows its beneficial effects against oxidative/nitrosative stress status, including that involving mitochondrial dysfunction (Acuña Castroviejo et al., 2011) .Treatment of FM patients with 3 mg melatonin daily for 30 days significantly improved the tender point count, severity of pain, global physical assessments, and sleep (Citera et al., 2000) . Moreover, in a limited number of cases, administration of 6 mg/day melatonin to patients with FMS resulted in normal sleep/wake cycles, normal diurnal activity, lack of pain, and fatigue and claims significant improvement of the behavioral symptoms including lack of depression (Acuna-Castroviejo et al., 2006) . Recently, in a double-blind, placebo-controlled clinical study was demonstrated that administration of melatonin, alone or in a combination with fluoxetine, was effective in the treatment of patients with FM (Hussain et al., 2011) . The "Myers' cocktail", an intravenous vitamin-andmineral formula (IVMT) for the treatment of a wide range of clinical conditions, which has vitamin c as antioxidant, has been assayed also, and most subjects experienced relief as compared to baseline, but no statistically significant differences were seen between IVMT and placebo (Ali et al., 2009) . Vitamin D which controls calcium and phosphorus metabolism (Norman et al, 1992) , is also a membrane antioxidant (Wiseman H, 1993) whose deficiency has been linked to chronic pain, muscle weakness (Straube et al, 2009; Zhang et al, 2010) and fibromyalgia (Armstrong et al 2007) . Subsequently, studies evaluating the effects of high-dose vitamin D treatment have been demonstrated to improve clinical symptoms in FM (Badsha et al 2009) .
One of the most investigated non-pharmacological therapies in the treatment of FM is moderate aerobic exercise, which has found some improvement in patients (Stephens et al., 2008) . A long-term combination of aerobic exercise, strengthening and flexibility improves psychological health status and health-related quality of life in patients with fibromyalgia (Sañudo et al., 2011) . Aquatic exercise program also has showed an improvement on symptoms an anti-inflammatory effect in FM (Ortega et al., 2010) . Interestingly, exercise therapies have been shown to provide significant benefits in patients with mitochondrial diseases because they induce an increase in mitochondrial biogenesis and an increase of the same size, which is proposed as an alternative therapeutic strategy in these conditions (Adhihetty et al., 2007; Safdar et al., 2011a) . PGC-1 , an important regulator of mitochondrial biogenesis via regulating transcription of nuclear-encoded mitochondrial genes, is increased by exercise (Safdar et al., 2011b) . This may explain to some extent the improvement seen in patients with FM. Antioxidant treatment combined with exercise has also been shown to modulate oxidative stress markers in FM patients (Nazıroğlu et al, 2010) 
Conclusion
Mitochondria and oxidative stress may play an essential role in the pathophysiology of FM. Since oxidative stress may either arise as a consequence of mitochondrial dysfunction or else interfere with mitochondrial function, reducing oxidative stress emerges as a form of mitochondrial medicine that could be beneficial in FM patients. Given the potential problems that can obscure any scientific enterprise, inconsistent results across studies are bound to occur. How are we to decide what is true? Let's turn to philosophy for a reasonable answer. The mathematician-philosopher Bertrand Russell approached a similar problem in his monograph The Problems of Philosophy (Russell B, 1912) . He addressed the following question: How do we know that anything is "real"? Is the only reality subjective and simply in our minds, as Bishop Berkley challenged, or can we mostly believe the objective reality? His pragmatic answer: All possibilities may be true, but when the preponderance of evidence indicates that objective reality and knowledge are the most probable case, go with it. If the preponderance of all evidence about the clinical description of fibromyalgia and it's pathogenic mechanisms and treatment strategies indicate a highly probable interrelated hypothesis, go with it. The direction of the literature on the whole trumps the less likely tangents. At the same time, remember Bertrand Russell and his pragmatic answer, and keep an open mind.
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